XBiotech's True Human antibody therapy for staph infections is derived from an antibody cloned from a natural human immune response and is designed to enable the patient's immune system to naturally, safely, and effectively eradicate the S. aureus infection.
XBiotech's chief executive officer, John Simard, said, "This is a case where the advantages of true human antibodies represent a quantum advance that goes well beyond safety. Identifying a precise antibody among the donor population that neutralizes a pathogen allows for the development of targeted anti-infective therapy with a potential for safety and efficacy unlike anything that has been marketed to date. We are very excited about what this therapy represents. And the intellectual property we have now acquired helps to expand the possibilities for our development efforts in this very important area of medicine."